DLL4 expression was also examined in two other in vitro models of PAH, our CAV1 (29) and SMAD8/9 LOF models, both of which have been shown to activate AKT (unpublished data for SMAD8/9). Here, DLL4 is linked to pulmonary arterial hypertension.